Company intelligence / Profile preview
Sravathi AI Technology
- Ownership
- Private
- Employees
- ~24
- Development stage
- Preclinical
Overview
Sravathi AI Technology leverages proprietary artificial intelligence platforms to accelerate the discovery of novel small molecules—including new chemical entities and repurposed drugs—primarily targeting oncology. Their ENPP1 inhibitor program for cancer exemplifies their preclinical pipeline. The company provides integrated solutions spanning computational prediction to in vitro validation and collaborates with partners globally to advance pharmaceutical R&D efficiently.
- Therapeutic areas
- OncologyOther
- Modalities
- Small moleculeDrug repurposing (as a modality of discovery)New chemical entity (NCE) designFormulation developmentPeptides (possible based on broad chemistry focus)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Sravathi AI Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sravathi AI Technology.